Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | PDE5A | O76074 | 13/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29481280 | 1.00 | CLK4 (0.40) | CLK4MAPK1USP2LMNACYP1A2 | |
| SCHEMBL22714768 | 0.87 | P2RX3 (0.45) | CLK4MAPK1USP2LMNACYP1A2 | |
| SCHEMBL29481339 | 0.87 | P2RX3 (0.45) | CLK4MAPK1USP2LMNACYP1A2 | |
| SCHEMBL28726614 | 0.87 | CLK4 (0.39) | CLK4MAPK1USP2LMNACYP1A2 | |
| SCHEMBL29481335 | 0.87 | CLK4 (0.39) | CLK4MAPK1USP2LMNACYP1A2 | |
| SCHEMBL29481199 | 0.85 | CLK4 (0.42) | CLK4MAPK1USP2LMNACYP1A2 | |
| SCHEMBL28726477 | 0.85 | CLK4 (0.42) | CLK4MAPK1USP2LMNACYP1A2 | |
| SCHEMBL29481352 | 0.85 | CLK4 (0.40) | CLK4MAPK1USP2LMNACYP1A2 | |
| SCHEMBL28726609 | 0.85 | CLK4 (0.40) | CLK4MAPK1USP2LMNACYP1A2 | |
| SCHEMBL29481207 | 0.85 | P2RX3 (0.44) | CLK4MAPK1USP2LMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637451-B2 | Amino quinazoline derivatives as P2X3 inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2026-05-26 | — | — | US | claimed |
| CN-118239931-A | As P2X3Aminoquinazoline derivatives of inhibitors | 奇斯药制品公司 | 2024-06-25 | — | — | CN | claimed |
| CN-114269432-B | As P2X3Aminoquinazoline derivatives of inhibitors | 奇斯药制品公司 | 2024-05-07 | — | — | CN | claimed |
| US-20230092892-A1 | AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS | CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) | 2023-03-23 | — | — | US | claimed |
| EP-3976179-A1 | AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2022-04-06 | — | — | EP | claimed |
| CN-114269432-A | As P2X3Aminoquinazoline derivatives as inhibitors | 奇斯药制品公司 | 2022-04-01 | — | — | CN | claimed |
| WO-2020239951-A1 | AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2020-12-03 | — | — | WO | claimed |
| US-12637451-B2 | Amino quinazoline derivatives as P2X3 inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2026-05-26 | — | — | US | disclosed |
| US-12466820-B2 | Amino quinazoline derivatives as P2X3 inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2025-11-11 | — | — | US | disclosed |
| EP-4251620-B1 | AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS | CHIESI FARM SPA (IT) | 2025-04-16 | — | — | EP | disclosed |
| CN-118239931-A | As P2X3Aminoquinazoline derivatives of inhibitors | 奇斯药制品公司 | 2024-06-25 | — | — | CN | disclosed |
| CN-114269432-B | As P2X3Aminoquinazoline derivatives of inhibitors | 奇斯药制品公司 | 2024-05-07 | — | — | CN | disclosed |
| CN-113891745-B | As P2X3Aminoquinazoline derivatives of inhibitors | 奇斯药制品公司 | 2024-05-07 | — | — | CN | disclosed |
| US-20220227749-A1 | AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS | CHARLES RIVER LABORATORIES, INC. | 2022-07-21 | — | — | US | disclosed |
| WO-2022112490-A1 | AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2022-06-02 | — | — | WO | disclosed |
| EP-3976179-A1 | AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2022-04-06 | — | — | EP | disclosed |
| CN-114269432-A | As P2X3Aminoquinazoline derivatives as inhibitors | 奇斯药制品公司 | 2022-04-01 | — | — | CN | disclosed |
| CN-113891745-A | As P2X3Aminoquinazoline derivatives as inhibitors | 奇斯药制品公司 | 2022-01-04 | — | — | CN | disclosed |
| WO-2020239952-A1 | AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2020-12-03 | — | — | WO | disclosed |
| WO-2020239951-A1 | AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2020-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220227749-A1 | AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS | P2RX3, P2RX5, P2RX1 | CLK4 3322/4885MAPK1 1131/4885USP2 3470/4885 |
| US-12466820-B2 | Amino quinazoline derivatives as P2X3 inhibitors | P2RX3, P2RX5, P2RX1 | CLK4 3322/4885MAPK1 1131/4885USP2 3470/4885 |
| US-20230092892-A1 | AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS | P2RX3, P2RX5, P2RX1 | CLK4 3322/4885MAPK1 1131/4885USP2 3470/4885 |
| US-12637451-B2 | Amino quinazoline derivatives as P2X3 inhibitors | P2RX3, P2RX1, P2RX7 | CLK4 3005/4885MAPK1 1538/4885USP2 3723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.